Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06921603 · ClinicalTrials.gov registry record · NA

POCUS-Guided Diuresis for Decompensated Heart Failure

A NA study of Heart Decompensation, Acute and Acute Kidney Injuries, sponsored by University of Pittsburgh.

Recruiting
Registry status
NA
Development phase
588
Enrollment target
5
Study locations

NCT06921603: Recruiting NA study of Heart Decompensation, Acute and Acute Kidney Injuries, sponsored by University of Pittsburgh.

NCT06921603 is a NA study of Heart Decompensation, Acute and Acute Kidney Injuries that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 588 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06921603, a NA study of Heart Decompensation, Acute and Acute Kidney Injuries, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
NA
Development phase
588 participants
Enrollment target
5
Study locations

Study Summary

Heart failure occurs when the heart cannot pump blood effectively, leading to fluid buildup in the body. This can cause problems such as difficulty breathing, swelling, and extreme tiredness. In severe cases, these symptoms worsen to the point where hospitalization is required. Unfortunately, many patients with severe heart failure are readmitted to the hospital within 30 days after discharge, which is both physically and emotionally challenging for patients and places a significant financial burden on individuals and the healthcare system. Although symptoms such as difficulty breathing and swelling may improve during the hospital stay, some patients are discharged with excess fluid remaining in their bodies. This retained fluid often causes symptoms to worsen, leading to subsequent hospital readmissions. Inadequate management of fluid levels can also harm the kidneys, further complicating the patient's condition. This study aims to improve care for heart failure patients by utilizing a simple, non-invasive tool to assess fluid levels more accurately at the bedside. The tool measures the size of a large blood vessel in the neck, providing key information about the pressure inside the heart. This information enables clinicians to determine the appropriate amount of medication needed to remove just the right amount of fluid. Properly managing fluid levels can help prevent kidney damage and improve overall patient outcomes. The primary goal of this study is to evaluate whether this tool can reduce the number of patients readmitted to the hospital within 30 days of discharge. A secondary goal is to determine whether the tool can help protect kidney function by allowing for better fluid management. If successful, this approach has the potential to help heart failure patients stay healthier, reduce hospital visits, and lower healthcare costs.

Primary Outcome

The percentage of participants readmitted to the hospital within 30 days of discharge for heart failure-related issues. The outcome compares the readmission rates between the POCUS-assessed diuretic management group and the standard care group.

Interventions

  • OTHER Furosemide (Standard Diuretic) Treatment
  • OTHER POCUS-Assessed Diuretic Management

Study Locations (5)

Pennsylvania

  • UPMC East - Pittsburgh
  • University of Pittsburgh Medical Center - Pittsburgh
  • UPMC Presbyterian - Pittsburgh
  • UPMC Mercy - Pittsburgh
  • UPMC Shadyside - Pittsburgh

Trial Details

FieldValue
Enrollment Target 588 participants
Start Date 2025-06-29
Est. Completion 2026-12
Phase NA
University of Pittsburgh

1,238 total trials

What NCT06921603 shows while recruiting

NCT06921603 is an interventional study that assigns participants to a tested intervention. The registered 588 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower).

The record links to 2 conditions, with Heart Decompensation, Acute appearing as the primary indexed condition, and to 2 interventions - of which Furosemide (Standard Diuretic) Treatment is the first listed.

NCT06921603 lists 5 locations in 1 state (Pennsylvania).

Frequently Asked Questions

What is clinical trial NCT06921603 about?

NCT06921603 is a clinical study titled "POCUS-Guided Diuresis for Decompensated Heart Failure". Heart failure occurs when the heart cannot pump blood effectively, leading to fluid buildup in the body. This can cause problems such as difficulty breathing, swelling, and extreme tiredness. In severe cases, these symptoms worsen to the point where hospitalization is required. Unfortunately, many p...

What is the current status of trial NCT06921603?

This trial is currently recruiting. It is a NA study. The enrollment target is 588 participants. The study started on 2025-06-29. Estimated completion is 2026-12.

What conditions does trial NCT06921603 study?

This clinical trial studies the following conditions: Heart Decompensation, Acute, Acute Kidney Injuries.

What interventions are being tested in trial NCT06921603?

The interventions under investigation include: Furosemide (Standard Diuretic) Treatment (OTHER), POCUS-Assessed Diuretic Management (OTHER).

Who is sponsoring clinical trial NCT06921603?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06921603 being conducted?

This trial has 5 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT06921603's enrollment target sits among peer trials

588 176th of 2000 higher than 1,825 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06986954 · 588 participants

    Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study

  • NCT01365169 · 590 participants · NA

    Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

  • NCT03774758 · 590 participants

    Biomarkers for Risk Stratification in Lung Cancer

  • NCT04747626 · 590 participants · NA

    B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06921603, the US trial registry maintained by the National Library of Medicine. NCT06921603 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.